References
- Kaplon H, Reichert JM. Antibodies to watch in 2019. mAbs. 2019;11:219–11. doi:https://doi.org/10.1080/19420862.2018.1556465.
- Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:https://doi.org/10.3389/fimmu.2014.00520.
- Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9(1):63–73. doi:https://doi.org/10.1007/s13238-017-0473-8.
- van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844):1554–57. doi:https://doi.org/10.1126/science.1144603.
- Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27(8):767–71. doi:https://doi.org/10.1038/nbt.1553.
- Correia IR. Stability of IgG isotypes in serum. mAbs. 2010;2(3):221–32. doi:https://doi.org/10.4161/mabs.2.3.11788.
- Trexler-Schmidt M, Sargis S, Chiu J, Sze-Khoo S, Mun M, Kao YH, Laird MW. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing. Biotechnol Bioeng. 2010;106:452–61. doi:https://doi.org/10.1002/bit.22699.
- Handlogten MW, Zhu M, Ahuja S. Glutathione and thioredoxin systems contribute to recombinant monoclonal antibody interchain disulfide bond reduction during bioprocessing. Biotechnol Bioeng. 2017;114:1469–77. doi:https://doi.org/10.1002/bit.26278.
- Kao YH, Hewitt DP, Trexler-Schmidt M, Laird MW. Mechanism of antibody reduction in cell culture production processes. Biotechnol Bioeng. 2010;107:622–32. doi:https://doi.org/10.1002/bit.22848.
- Koterba KL, Borgschulte T, Laird MW. Thioredoxin 1 is responsible for antibody disulfide reduction in CHO cell culture. J Biotechnol. 2012;157:261–67. doi:https://doi.org/10.1016/j.jbiotec.2011.11.009.
- Chung WK, Russell B, Yang Y, Handlogten M, Hudak S, Cao M, Wang J, Robbins D, Ahuja S, Zhu M, et al. Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability. Biotechnol Bioeng. 2017;114(6):1264–74. doi:https://doi.org/10.1002/bit.26265.
- O’Mara B, Gao ZH, Kuruganti M, Mallett R, Nayar G, Smith L, Meyer JD, Therriault J, Miller C, Cisney J, et al. Impact of depth filtration on disulfide bond reduction during downstream processing of monoclonal antibodies from CHO cell cultures. Biotechnol Bioeng. 2019;116(7):1669–83. doi:https://doi.org/10.1002/bit.26964.
- Swope N, Chung WK, Cao M, Motabar D, Liu D, Ahuja S, Handlogten M. Impact of enzymatic reduction on bivalent bispecific antibody fragmentation and loss of product purity upon reoxidation. Biotechnol Bioeng. 2020;117:1063–71.
- Handlogten MW, Wang J, Ahuja S. n/a. Online control of cell culture redox potential prevents antibody interchain disulfide bond reduction.
- Derfus GE, Dizon-Maspat J, Broddrick JT, Velayo AC, Toschi JD, Santuray RT, Hsu SK, Winter CM, Krishnan R, Amanullah A, et al. Red colored IgG4 caused by vitamin B12 from cell culture media combined with disulfide reduction at harvest. mAbs. 2014;6(3):679–88. doi:https://doi.org/10.4161/mabs.28257.
- Silva JP, Vetterlein O, Jose J, Peters S, Kirby H. The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J Biol Chem. 2015;290:5462–69. doi:https://doi.org/10.1074/jbc.M114.600973.
- Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, Pedley B, Adair JR. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993;30(1):105–08. doi:https://doi.org/10.1016/0161-5890(93)90432-B.
- Poole LB. The basics of thiols and cysteines in redox biology and chemistry. Free Radic Biol Med. 2015;80:148–57. doi:https://doi.org/10.1016/j.freeradbiomed.2014.11.013.
- Hutterer KM, Hong RW, Lull J, Zhao X, Wang T, Pei R, Le ME, Borisov O, Piper R, Liu YD, et al. Monoclonal antibody disulfide reduction during manufacturing: untangling process effects from product effects. mAbs. 2013;5(4):608–13. doi:https://doi.org/10.4161/mabs.24725.
- Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem. 2010;82:5219–26. doi:https://doi.org/10.1021/ac100575n.
- Montano RF, Morrison SL. Influence of the isotype of the light chain on the properties of IgG. J Immunol. 2002;168:224–31. doi:https://doi.org/10.4049/jimmunol.168.1.224.
- Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, Kohnert U. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos. 2010;38:84–91. doi:https://doi.org/10.1124/dmd.109.029751.
- Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: the Architect behind the immune and nonimmune functions of IgG and albumin. J Immunol. 2015;194:4595–603. doi:https://doi.org/10.4049/jimmunol.1403014.
- Stewart R, Hammond SA, Oberst M, Wilkinson RW. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J. ImmunoTher. Cancer. 2014;2:29. doi:https://doi.org/10.1186/s40425-014-0029-x.
- Gong Q, Hazen M, Marshall B, Crowell SR, Ou Q, Wong AW, Phung W, Vernes J-M, Meng YG, Tejada M, et al. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation. mAbs. 2016;8(6):1098–106. doi:https://doi.org/10.1080/19420862.2016.1189049.
- Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, Fodor S, Kelner DN, Flynn GC, Liu YD, et al. Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem. 2008;283(23):16194–205. doi:https://doi.org/10.1074/jbc.M709987200.
- Scapin G, Yang X, Prosise WW, McCoy M, Reichert P, Johnston JM, Kashi RS, Strickland C. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol. 2015;22(12):953–58. doi:https://doi.org/10.1038/nsmb.3129.
- Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One. 2012;7(5):e36412. doi:https://doi.org/10.1371/journal.pone.0036412.
- Bezabeh B, Fleming R, Fazenbaker C, Zhong H, Coffman K, Yu X-Q, Leow CC, Gibson N, Wilson S, Stover CK, et al. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. mAbs. 2017;9(2):240–56. doi:https://doi.org/10.1080/19420862.2016.1270492.